Two LEAPs Behind: Merck/Eisai Post Pair Of Failures Of Keytruda/Lenvima Combo
The announcement that LEAP-006 and LEAP-008, both in non-small cell lung cancer, did not meet their primary endpoints adds to a string of failures for the combination.
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: major Q4 catalysts; Verona’s COPD contender; Alfasigma acquires Intercept; more setbacks for Keytruda/Lenvima combo; and new pressures on China IPOs.
The combination of Keytruda plus Eisai’s Lenvima combination may be reaching the limit of its potential, but the US giant’s blockbuster PD-1 therapy has plenty more opportunities to maintain its growth for the next five years.
The partners’ combination of Keytruda and Lenvima has missed the mark in two pivotal trials in melanoma and colorectal cancer, leading to one trial discontinuation and dashing hopes for important label expansions.